Unilever slides and GSK bounces after GSK knocks back £50bn bid
Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
Shares in consumer-products giant Unilever fell by more than 7% today to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
Both GSK and Pfizer, which holds a 32% stake in the division, believe the unit is worth at least £60bn.
Shares in GSK, which has been planning to sell the division for more than a year, rose 4% on the news.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Unilever meanwhile tried to reassure its shareholders that the company won’t be dragged into a bidding war for the unit. “Please be assured Unilever will not overpay for any asset, particularly in the context where GSK consumer health is a very attractive option in the consumer health space. But it’s not the only option,” Unilever’s chief executive Alan Jope said.
GSK’s current plan is to spin the consumer unit out as a separate listed company later this year, in order to focus on its vaccines and pharma business.
Laura Hoy at Hargreaves Lansdown notes that one reason why GSK/Pfizer may have rejected the latest bid is because rising inflation puts companies with strong brands (and therefore pricing power) in a good position “if consumers start to pare back spending.” GSK expects the unit’s organic sales to grow by 4%-6% per year.
But given the appeal of the unit, says Hoy, investors shouldn’t rule out another bid by Unilever. After all, GSK’s brands are highly appealing given Unilever’s increased focus on health, beauty and hygiene, and it has admitted that it is looking for acquisition opportunities in the sector. “With Unilever’s tea business expected to bring in upwards of £4bn when it’s sold later this year, management might have the firepower to sweeten the deal.”
If a deal was done, it would, says the FT, “be one of the largest ever on the London market”, outstripped only by the 1999 purchase of Germany group Mannesmann by Vodafone, and the 2016 purchase of SABMiller by AB InBev. That might cause problems in the longer run.
“Unilever already has relatively high leverage, and by paying largely in cash, you would have a highly levered new company that would have to focus for years on paying debt rather than driving growth,” Bruno Monteyne of brokerage Bernstein tells the FT.
Unilever has come under scrutiny recently after fund manager Terry Smith – founder and chief executive of Fundsmith, and Unilever’s ninth biggest shareholder – vented his frustration in his annual letter to fundholders, claiming the company is “obsessed with publicly displaying sustainability credentials at the expense of focusing on the fundamentals of the business”.
Activist hedge funds with stakes in GSK – which has long been one of the FTSE 100’s “dullest” stocks for its long-suffering shareholders – welcomed the bid. One such activist, Giuseppe Bivona of Bluebell Partners, told Bloomberg: “It’s a great asset and there should be broad interest in it.”
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Saloni is a web writer for MoneyWeek focusing on personal finance and global financial markets. Her work has appeared in FTAdviser (part of the Financial Times), Business Insider and City A.M, among other publications. She holds a masters in international journalism from City, University of London.
Follow her on Twitter at @sardana_saloni
-
How to invest in nuclear power
We need nuclear power to go green, says Dominic Frisby. But there is a better option than huge power stations
By Dominic Frisby Published
-
Chase slashes its easy-access savings rate – is it time to switch?
The Chase easy-access savings account has proved popular with savers thanks to its competitive rate and bonus deals. But, as the rate has dropped, has it lost its charm?
By Katie Williams Published
-
Halifax: House price slump continues as prices slide for the sixth consecutive month
UK house prices fell again in September as buyers returned, but the slowdown was not as fast as anticipated, latest Halifax data shows. Where are house prices falling the most?
By Kalpana Fitzpatrick Published
-
Rents hit a record high - but is the opportunity for buy-to-let investors still strong?
UK rent prices have hit a record high with the average hitting over £1,200 a month says Rightmove. Are there still opportunities in buy-to-let?
By Marc Shoffman Published
-
Pension savers turn to gold investments
Investors are racing to buy gold to protect their pensions from a stock market correction and high inflation, experts say
By Ruth Emery Published
-
Where to find the best returns from student accommodation
Student accommodation can be a lucrative investment if you know where to look.
By Marc Shoffman Published
-
Best investing apps
We round up the best investing apps. Looking for an easy-to-use app to help you start investing, keep track of your portfolio or make trades on the go?
By Ruth Emery Last updated
-
The world’s best bargain stocks
Searching for bargain stocks with Alec Cutler of the Orbis Global Balanced Fund, who tells Andrew Van Sickle which sectors are being overlooked.
By Andrew Van Sickle Published
-
Revealed: the cheapest cities to own a home in Britain
New research reveals the cheapest cities to own a home, taking account of mortgage payments, utility bills and council tax
By Ruth Emery Published
-
UK recession: How to protect your portfolio
As the UK recession is confirmed, we look at ways to protect your wealth.
By Henry Sandercock Last updated